Percutaneous vena cava superior angioplasty and stenting as an effective method of treatment in vena cava superior syndrome in the course of lung cancer Case report

Article Sidebar

PDF


Published: Sep 30, 2014
Keywords:
vena cava syndrome, vena cava superior stenting, lung cancer

Main Article Content

Szymon Darocha
Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre Otwock, Poland
Sebastian Szmit
Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre Otwock, Poland
Radosław Pietura
Department of Radiography, Medical University of Lublin, Poland
Marcin Kurzyna
Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, European Health Centre Otwock, Poland

Abstract

Vena cava superior syndrome (VCSS) is a sudden life-threatening condition encountered in patients with neoplasms. The prognosis depends on histopathological diagnosis, severity of clinical symptoms and administered treatment. Depending on the type of neoplasm, the treatment of choice may be radiotherapy or chemotherapy. In patients with rapidly increasing clinical symptoms the justified management is percutaneous balloon angioplasty of the superior vena cava with the placement of stents.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Darocha S, Szmit S, Pietura R, Kurzyna M. Percutaneous vena cava superior angioplasty and stenting as an effective method of treatment in vena cava superior syndrome in the course of lung cancer. OncoReview [Internet]. 2014Sep.30 [cited 2024Jul.23];4(3(15):108-12. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/368
Issue
Vol 4 No 3(15) (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Escalante CP. Causes and management of superior vena cava syndrome. Oncology 1993; 7: 61-8.
2. Ganeshan A, Hon LQ, Warakaulle DR et al. Superior vena caval stenting for SVC obstruction: current status. Eur J Radiol 2009; 71(2): 343-9.
3. Kowalski DM, Krzakowski M. Zespół żyły głównej górnej – rozpoznawanie i leczenie. In: Postępowanie w powikłaniach sercowo-naczyniowych w raku płuca. Rekomendacje Krajowego Nadzoru Kardiologicznego i Onkologicznego dotyczące bezpieczeństwa kardiologicznego u chorych na raka płuca. Krzakowski M, Opolski G, Szmit S (ed.). Medical Education, Warszawa 2012: 21-29.
4. You JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome – a proposed classification system and algorithm for management. J Thorac Oncol 2008; 3: 811-814.
5. Wilson LD, Detterbeck FC, Yahalom J. Superior vena cava syndrome with malignant causes. N Engl J Med 2007; 356: 1862-1869.
6. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev 2001(4): CD001316.
7. Sobrinho G, Aguiar P. Stent placement for the treatment of malignant superior vena cava syndrome – a single center series of 56 patients. Arch Bronconeumol 2014; 50(4): 135-40.